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The impact of age on hospital mortality, incidence of major 
hemorrhagic events and transfusion requirements was ex- 
amined in 756 patients with acute myocardial infarction 
enrolled in the Thrombolysis in Myocardial Infarction 
(TIMI) Phase I, open label studies and the TIM1 Phase II 
pilot study. The mortality rate significantly increased with 
age and was 3.5%, 11.5% and 12% in patients <65, 65 to 
69 and 70 to 76 years of age, respectively (p < 0.001). 
Logistic regression analyses selected female gender, diabe- 
tes mellitus, extensive coronary artery disease, history of 
congestive heart failure, continuing chest pain immediately 
after recombinant tissue-type plasminogen activator (rt- 
PA) administration, low systolic blood pressure at the time 
of admission and advanced age as variables predictive of 
in-hospital death. 
The incidence of major hemorrhagic events among 
patients not undergoing cardiac surgery during hospitaliza- 
tion was 8.7%, 14.5% and 24.7% in patients aged <65,65 
to 69 and 270 years, respectively (p < 0.001). The majority 
of hemorrhages were secondary to cardiac catheterization 
or puncture wounds. Variables related to a major hemor- 
rhagic event included protocol, age, rt-PA dose/kg body 
weight and elevated diastolic blood pressure on admission. 
Of five intracranial bleeding events, three occurred in 
patients >65 years. Transfusion requirements significantly 
increased with age (p < 0.001). Reperfusion status at 90 
min in the TIM1 Phase I and open label studies A to C was 
similar in the three age groups studied and ranged from 
60% to 71%. 
Thus, a strategy of early cardiac catheterization in older 
patients with acute myocardial infarction treated with 
thrombolytic therapy is associated with an increased hos- 
pital mortality rate and incidence of bleeding compared 
with findings in younger patients. A randomized placebo- 
controlled trial appears to be needed to determine safety 
and efficacy of rt-PA therapy in patients >76 years. 
(J Am Co11 Cardiol 1989;14:1159-65) 
Elderly patients with acute myocardial infarction represent a 
high risk subset with increased morbidity and mortality 
compared with those in younger patients (I-IO). Throm- 
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bolytic therapy and coronary angioplasty improve perfusion 
in infarct-related vessels and have the potential to limit 
myocardial infarct size when initiated early after symptom 
onset (1 l-17). Recombinant tissue-type plasminogen activa- 
tor (rt-PA) is superior to streptokinase in restoring patency 
of initially occluded infarct-related vessels (18-20). How- 
ever, data on the use of thrombolytic therapy in elderly 
patients are limited because most thrombolytic trials exclude 
patients >75 years and increased hemorrhagic complications 
were noted in one observational study (6) that used strep- 
tokinase in older patients. There are limited data that de- 
scribe the use of rt-PA as therapy for acute myocardial 
infarction in older patients (7,211. 
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This study was performed to evaluate the clinical expe- 
rience with r&PA for acute myocardial infarction in older 
patients enrolled in the Thrombolysis in Myocardial Infarc- 
tion (TIMI) Phase I, open label studies and the TIMI Phase 
II pilot study and to compare morbidity and mortality with 
those observed in younger patients. The effect of age as an 
independent risk factor contributing to in-hospital mortality 
and hemorrhagic events was tested with multiple logistic 
regression analyses. 
Methods 
Study design. The patient selection and exclusion criteria 
in the TIM1 study have been previously described (20, 
22-24). To be eligible for treatment, patients were required 
to satisfy the following criteria: 1) chest pain characteristic 
of myocardial ischemia for 230 mitt; 2) ST segment elevation 
20.1 MV in at least two electrocardiographic (ECG) leads, 
reflecting a singular vascular territory; and 3) elapsed time 
from onset of ischemic pain to recruitment <7 h in TIM1 
Phase I and open label studies A to C and <4 h in open label 
study D and the TIM1 Phase II pilot study; 4) the TIM1 Phase 
I study required angiographic entry criteria of a ~50% 
obstruction in the infarct-related vessel, and open label 
studies A to C required complete or subtotal obstruction of 
the infarct-related vessel (TIM1 grade 0 or 1 flow) before 
initiation of &PA administration. Patients were not eligible 
if the ECG at presentation could not be interpreted for acute 
myocardial infarction or if the patient had the potential for 
significant hemorrhagic complications. 
Study groups. The TIMI Phase I study (19) was a ran- 
domized trial comparing intravenous streptokinase with in- 
travenous rt-PA. The 143 patients in Phase I included in the 
present report were treated with rt-PA. In this trial, r&PA 
GllO21 (roller bottle preparation) was infused intravenously 
over 3 h in doses of 40, 20 and 20 mg in successive hours. 
The drug was administered at the time of cardiac catheter- 
ization after visualization of the coronary arteries. Systemic 
heparinization was employed for 7 to 10 days. The subse- 
quent open label studies and the Phase II pilot study used 
suspension culture rt-PA. In the latter studies, the total dose 
and dose rate of rt-PA were evaluated to determine the 
optimal regimen to achieve early and late patency of the 
infarct-related vessel (Table 1). 
In open label studies, A to C, rt-PA was administered in 
the cardiac catheterization laboratory after identification of 
an occluded infarct-related vessel, whereas in open label 
study D and the Phase II pilot study, cardiac catheterization 
was scheduled in most patients at 18 to 48 h after rt-PA 
therapy. In each open label study, patients received sys- 
temic heparinization for at least 5 days with the dosage 
adjusted to maintain the activated partial thromboplastin 
time at 1.5 to 2.5 times the upper limit of normal, 80 mg/day 
of aspirin and dipyridamole 75 mg four times daily. Aspirin 
Table 1. Recombinant Tissue-Type Plasminogen Activator @-PA) 
Dosing Requirements: TIM1 Phase I, Open Label A to D and 
TIM1 Phase II Pilot Studies 
Date Trial 
rt-PA Dose (mg)/Duration of Infusion 
Study Started No. Ih 2h 3h 4h Sh 6h 
Phase I* 
Open 
label 
A 
B 
C 
D 
TIM1 II 
pilot? 
08/20/84 143 40 20 20 
08/05/85 48 40 20 20 
09117185 88 60 20 20 
12109185 65 9181 20 10 10 10 IO 
02/08/86 42 9/81 20 IO 10 10 10 
03117186 370 9/81 20 10 10 10 10 
*Roller bottle preparation of r&PA. ‘FDosage used in 317 patients; 53 
patients received a study dosage of 6/54,20,5,5,5,5 or 100 mg of rt-PA. 9/81 = 
9 mg bolus followed by 81 mg infusion. 
was increased to 325 mg three times daily when the intrave- 
nous heparin infusion was stopped. Patients in the Phase II 
pilot study received systemic heparinization for at least 5 
days, with the dosage adjusted as in the open label studies 
and aspirin increased to 325 mg when the heparin infusion 
was discontinued. In the open label study D and the Phase II 
pilot study, heparin therapy was decreased to half strength 
4 h before cardiac catheterization. Each protocol was ap- 
proved by the institutional review board at participating 
institutions, and written informed consent was obtained 
from each enrolled patient. 
Classification of major hemorrhagic events. Hemorrhagic 
events were classified by the Hemorrhagic Event Review 
Committee, which reviewed case reports of all patients who 
had a blood transfusion, a decrease in hemoglobin 23.0 g/d1 
or an observed blood loss. A major hemorrhagic event was 
defined as a decrease in hemoglobin >5 g/d1 (or >15% 
decrease in hematocrit), pericardial hemorrhage with tam- 
ponade or any intracranial bleeding. The Committee also 
noted the location, spontaneity and onset of the major 
hemorrhagic event. 
Statistical analysis. Group differences in outcome were 
assessed by the chi-square test for categorical variables. The 
reported probability values are two-sided and not adjusted 
for multiple testing. Multiple stepwise logistic regression 
analyses were used to choose a subset of variables that were 
most predictive of events (25). The outcome variables tested 
were in-hospital mortality and major hemorrhagic events. 
Categorical variables used in the stepwise logistic regression 
analyses were: prior use of antiplatelet drugs or anticoagu- 
lants; gender; history of diabetes; history of hypertension; 
number of vessels with >60% stenosis; history of myocar- 
dial infarction or of gastrointestinal disease, transient isch- 
emit attacks, congestive heart failure or angina; the presence 
of pulmonary rales at admission; continuing pain immedi- 
ately after t-t-PA administration; protocol phase; site of 
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Table 2. Patient Characteristics in TIM1 Studv Patients bv Ane Groun 
565 yr 65 to 69 yr 270 to 76 yr 
(n = 577) (n = 87) (n = 92) Total 
No. % No. % No. % No. % 
No. of men 493 85.4 59 67.8 56 60.9 608 80.4 
History 
Hypertension 
Previous Ml 
CHF 
Diabetes 
Angina pectoris 
GI disease 
Transient ischemic attack* 
226 39.2 
71 12.3 
6 1.0 
61 10.6 
236 40.9 
63 10.9 
13 2.3 
39 
18 
13 
36 
17 
3 
44.x 38 41.3 303 40.1 
20.7 19 20.6 I08 14.3 
I.2 4 4.4 II 1.5 
14.9 14 15.2 88 11.6 
41.4 43 46.7 315 41.7 
19.5 15 16.3 95 12.6 
3.4 5 5.4 21 2.7 
Infarct location 
Anterior 
Inferior 
Lateral 
Rales 
306 53.0 
256 44.4 
15 2.6 
97 16.8 
59 10.2 
44 
41 
2 
I5 
50.6 
47.1 
2.3 
17.2 
Cardiac surgery during 
hospitalization 
II 12.6 
51.1 397 52.5 
47.8 341 45.1 
I.1 I8 2.4 
26. I 136 18.0 
12.0 81 10.7 
Systolic blood pressure (mm Hg)t 131.5 125.9 129.8 130.6 
Diastolic blood pressure (mm Hg)+ 84.9 75.2 96.3 85.2 
Heart rate (beats/min)t 77.4 73.4 75.9 76.8 
Time from onset of symptoms to 216 206 223 216 
initiation of treatment (mitt)* 
Length of hospital stay (days): 12.0 12.5 15.2 12.4 
*As of August 22. 1986, because of potential risk of intracranial bleeding, patients with a history of transient ischemic attacks were excluded from entry into 
the TIM1 Phase II pilot study. tData reported as mean values. CHF = congestive heart failure. MI = myocardial infarction. 
qualifying myocardial infarction; cardiac surgery during hos- 
pitalization, and age category. Continuous variables used in 
the stepwise logistic regression analysis were systolic and 
diastolic blood pressure, heart rate, dose of rt-PA per 
kilogram of body weight and time from onset of symptoms to 
treatment with rt-PA. All statistical analyses were performed 
using BMDP or SAS statistical software package programs 
(26,27). The data and analyses presented in this report are 
based on all data forms received by the TIMI Coordinating 
Center as of August 1988. 
Hospital mortality. The mean (-tSD) length of stay in the 
hospital was 12.4 2 6.9 days. The average length of stay in 
the oldest age group was slightly longer than that in the two 
younger age groups (Table 2). There was a significant 
increase in the in-hospital mortality as age increased (p < 
0.001) (Fig. 1). Variables associated with an increase in 
in-hospital mortality (logistic regression analysis) included 
female gender, diabetes mellitus, number of diseased coro- 
nary vessels with ~60% stenosis history of congestive heart 
Figure 1. The in-hospital mortality rate was significantly increased in 
patients >65 years of age (p < 0.001). 
50 
45 
40 
Results 
Clinical characteristics. The clinical characteristics of the 
756 patients studied are illustrated in Table 2. Patients were 
grouped according to age as follows: ~65 (n = 577), 65 to 69 
(n = 87) and 70 to 76 years (n = 92). The percent of women 
significantly increased with age (p < O.OOl), and previous 
myocardial infarction was significantly more frequent in 
older patients (p = 0.009). We examined the age distribution 
among the TIM1 Phase I, open label studies and the TIM1 
Phase 11 pilot study and found that age distribution of 
patients younger and older than age 65 years was compara- 
ble in the different protocols. 
E 35 
5 30 pco.oo1 
g 25 
B 20 
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1162 CHAITMAN ET AL. 
TISSUE-TYPE PLASMINOGEN ACTIVATOR IN THE ELDERLY 
JACC Vol. 14, No. 5 
November 1, 1989: I 159-65 
Table 3. TIM1 Phase I and Open Label A to D and TIMI Phase II Pilot Patient Variables Significantly Related to In-Hospital Mortality as 
Determined by Logistic Regression 
Categorical Variables 
Gender 
History of diabetes 
No. of vessels with ~60% 
stenosis 
History of CHF 
Continuing pain immediately 
after rt-PA administration 
Age (yr) 
Continuous variable 
systolic blood pressure 
Group % Dead 
Male 4.1 
Female 10.8 
Yes 12.5 
No 4.5 
0 0 
1 2.3 
2 5.4 
3 14.3 
Yes 45.5 
No 4.8 
Yes 10.7 
No 3.8 
<65 3.5 
65 to 69 11.5 
270 12.0 
P 
(unadjusted) 
0.001 
0.002 
<O.OOl 
10.001 
<O.OOl 
<O.OOl 
(adj:ted) 
0.03 
0.06 
0.002 
0.008 
0.014 
0.034 
<O.ool 
Beta 
Coefficient 
-1.16 
- 
1.10 
- 
2.62 
3.50 
6.12 
3.94 
- 
1.19 
- 
- 
1.51 
0.22 
-0.03 
CHF = congestive heart failure. 
failure, continuing chest pain immediately after rt-PA admin- 
istration, low systolic blood pressure on admission, and age 
(Table 3). Age remained an important independent variable 
related to in-hospital mortality even after adjustment for the 
preceding covariates (p = 0.034). Of the 41 deaths observed, 
2 (4.9%) were due to a hemorrhagic event (1 patient died 
from gastrointestinal bleeding, the other from intracranial 
bleeding). 
Major hemorrhagic events. Every attempt was made to 
capture all potential bleeding events in the TIMI trial be- 
cause the study employed a powerful thrombolytic drug. The 
incidence of major hemorrhagic events among patients not 
undergoing cardiac surgery during hospitalization increased 
with age (p < 0.001) (Fig. 2). When the 106 patients classified 
as having had a major hemorrhagic event were reviewed to 
determine the primary site of hemorrhage, some age trends 
were found among the three age groups, although the event 
numbers were too small to obtain any reliable inference for 
site-specific events (Table 4). The most common site of a 
major hemorrhagic event was the site of previous catheter- 
ization. Of five intracranial bleeding events, four occurred in 
the Phase II pilot study, with an assigned &PA dose of 150 
mg administered over 6 h. The dose ,was subsequently 
reduced to 100 mg administered over 6 h in the last 53 
patients of the TIM1 Phase II pilot study (28,29). 
The performance of cardiac surgery was associated with 
an increased likelihood of major hemorrhagic events. Be- 
cause blood loss is a relatively common event in patients 
who have surgery, regardless of thrombolytic therapy, these 
events are confounded with the analysis of variables associ- 
ated with increased bleeding risk after thrombolytic therapy. 
Therefore, all subsequent analyses were performed exclud- 
ing patients who underwent cardiac surgery during hospital- 
ization. The incidence of major hemorrhagic events in the 
TIM1 Phase II pilot study, excluding those patients who 
underwent cardiac surgery during hospitalization, was 
Figure 2. The incidence of major hemorrhagic events among patients 
not receiving cardiac surgery significantly increased with age (p < 
0.001). The incidence of transfusions among those who had a major 
hemorrhagic event significantly increased with age. Solid area = 
transfusion; cross-batched area = no transfusion. 
50 - 
45 - 
40 - 
35 - 
2 30 p<o.o01 
w 
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Table 4. Sources of Major Hemorrhagic Events by Age Group 
Age (yr) 
<65 65 to 69 270 
(n = 577) (n = 87) (n = 92) 
Site No. % No. % No. % 
Intracranial 2 0.4 2 2.3 I I.1 
Gastrointestinal 7 1.2 I 1.1 4 4.3 
Retroperitoneal I 0.2 0 0.0 I 1.1 
Catheterization site 3 I 5.4 5 5.7 I2 13.0 
Other puncture site 2 0.4 3 3.5 I 1.1 
Other source 16 2.8 3 3.5 4 4.3 
Multiple sites 4 0.7 0 0.0 I I.1 
Loss >5 gidl Hb 3 0.4 2 2.3 0 0.0 
Minor hemorrhage 74 12.8 13 14.9 19 20.6 
No hemorrhage 437 75.7 58 66.6 49 53.3 
Hb = hemoglobin 
11.9% for patients receiving 150 mg of rt-PA and 10.6% for 
patients receiving <I50 mg of rt-PA (p = 0.31). 
Multiple logistic regression analysis selected protocol, 
age, dose of rt-PA per kilogram body weight and elevated 
diastolic blood pressure on admission as independent pre- 
dictors of a major hemorrhagic event (Table 5). 
The incidence of blood transfusions significantly in- 
creased with age and was 12.5%, 22.4% and 40.7% in 
patients <65,65 to 69 and 70 to 76 years of age, respectively 
(p < 0.001). Transfusion requirements in the TIM1 Phase II 
pilot and open label D studies were significantly less than in 
the TIM1 Phase I and open label studies A to C (12.3% 
versus 21.7%, respectively; p < 0.001). 
Reperfusion status. The reperfusion status at 90 min in 
TIM1 Phase I and open label studies A to C was examined. 
The percent of patients with TIM1 grade 2 or 3 flow at 90 min 
after rt-PA administration was 64.1%, 60.0% and 71% in 
patients ~65, 65 to 69 and 70 to 76 years of age, respectively 
(p = 0.61). 
Discussion 
In-hospital mortality. Information on the prognosis of 
older patients with acute myocardial infarction treated with 
rt-PA is limited. We analyzed the TIM1 Phase I, open label 
studies and Phase II pilot study to examine the incidence of 
in-hospital death and hemorrhagic events in older patients 
treated with rt-PA. Previously reported variables adversely 
affecting the mortality rate (such as a decreasing male/female 
ratio, previous myocardial infarction and pulmonary rales) 
were more common in the elderly, confirming previous 
reports (2,4,5) in the prethrombolytic era. Mortality was 
significantly increased in older patients, with an 11.5% to 
12% in-hospital mortality rate for patients ~65 years of age 
compared with 3.5% observed in patients ~65 years. Multi- 
ple logistic regression analyses selected age as an indepen- 
dent prognostic variable, even after adjustment for multiple 
covariates known to influence in-hospital mortality. These 
data confirm previous reports (2) in the prethrombolytic era 
in older patients. 
The explanation for an increased in-hospital mortality in 
older patients may be related to the greater extent of 
coronary artery disease and greater prevalence of previous 
myocardial infarction frequently found in older patients. 
Furthermore, older patients tend to present to the hospital 
later after symptom onset than do younger patients and may 
be denied therapeutic strategies that reduce myocardial 
infarct size and mortality (5). In this study, adjustment for 
these characteristics does not explain the relatively higher 
mortality rate in older compared with younger patients 
because these variables were either similar among the dif- 
ferent age groups or did not remove the effect of age on 
observed mortality differences in adjusted analyses. The 
Table 5. TIM1 Phase I and Open Label A to D and TIMI Phase II Pilot Patient Variables 
Significantly Associated With Major Hemorrhage as Determined by Logistic Regression in 
675 Patients* 
g With 
Major P P Beta 
Group Hemorrhage (unadjusted) (adjusted) Coefficient 
Categorical variables 
Protocol 1 13.9 - 
II Pilot 8.1 -2.06 
Open A to D 14.6 0.035 0.008 0.56 
Age (yr) 165 8.7 - 
65 to 69 14.5 -0.28 
270 24.7 <O.ool <O.OOl I .42 
Continuous Variables 
Diastolic blood pressure 0.06 -0.346 
Dose per kg body weight 0.006 0.90 
*Patients undergoing cardiac surgery during hospitalization were excluded from this analysis. 
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normal aging process in humans includes brown atrophy of 
the myocardium, with focal amyloid deposits and calcific 
deposition in the aortic valve, mitral anulus and epicardial 
coronary arteries. Diastolic myocardial stiffness and the 
autonomic response to stress are altered in elderly patients, 
and it is possible that these characteristics in such patients 
reduce the tolerance to an acute myocardial ischemic insult 
as compared with that in younger patients (30,31). 
Hemorrhagic complications. The incidence of bleeding 
complications after acute myocardial infarction is clearly 
related to the use of thrombolytic drugs, systemic heparin- 
ization and the performance of cardiac catheterization or 
cardiac surgery during or closely after the use of throm- 
bolytic therapy. In previous studies (14) of patients treated 
without thrombolytic therapy or cardiac catheterization, the 
incidence rate of bleeding was reported to be as low as 0.2%. 
The incidence rate of bleeding complications associated with 
the use of intravenous streptokinase is reported to be 3.8% 
to 19% (3,15,16). When cardiac catheterization is associated 
with streptokinase therapy and the drug is administered by 
the intracoronary route, the incidence of bleeding is reported 
to be 25% to 53% (13,17). Continued bleeding after cardiac 
catheterization may be related to the use of systemic hepa- 
rinization and antiplatelet drugs (32,33). 
In the TIM1 Phase I study, the incidence of major 
bleeding events after the administration of streptokinase or 
rt-PA was similar at 15.6% and 15.4%, respectively (33) and 
transfusion requirements were similar (33). Our data indicate 
that the incidence of hemorrhagic complications significantly 
increases in elderly patients and that major bleeding events 
may occur 2.8 times more frequently in patients >69 years of 
age as compared to those <65 years. Hemorrhage most 
commonly occurs at cardiac catheterization access sites or 
previous puncture wounds. Logistic regression analysis se- 
lected age as an independent predictor of a major hemor- 
rhagic event, even after adjustments for other known prog- 
nostic factors. The incidence of major hemorrhagic 
complications was directly related to the dose of rt-PA used, 
and may indicate that dose adjustment per kilogram of body 
weight would reduce the incidence of hemorrhagic events. 
Other thrombolytic trials. The Gruppo Italian0 per lo 
Studio della Streptochinasi nell’Infarto Miocardico (GISSI) 
(3) and International Study of Infarct Survival (ISIS 2) (8) 
trials, which compared intravenous streptokinase and pla- 
cebo, did not have an upper age limit in their patient 
inclusion criteria and did not require systemic heparinization 
or cardiac catheterization as part of the protocol design. The 
GISSI study did not show a significant treatment difference 
in mortality in patients >65 years, whereas the ISIS II study 
found a significant reduction in mortality with streptokinase 
in older patients. Neither study noted a significant difference 
in hemorrhagic events in older as compared with younger 
patients. The data are in contrast to those reported in the 
present study, where the strategy of thrombolytic therapy 
followed by systemic heparinization and urgent cardiac 
catheterization was employed. 
In contrast to the current study in which r&PA was used, 
the GISSI and ISIS II trials did not employ routine systemic 
heparinization after administration of streptokinase and 
treated a much larger sample of elderly patients with strep- 
tokinase. A larger sample size of elderly patients would 
provide more power to test the hypothesis that heparin has 
an effect on increased bleeding risk with age. The GISSI II 
trial, which is currently in progress, compares intravenous 
streptokinase with intravenous rt-PA and contains a second 
randomization sequence comparing systemic intravenous 
heparinization with placebo; the impact of concomitant use 
of heparin with rt-PA and impact of age is also being 
addressed. In the ASSET trial (7), where rt-PA therapy was 
compared with placebo, patients treated with rt-PA had a 
significant mortality reduction, even in the older age groups. 
The ASSET trial excluded patients >76 years of age. Lew et 
al. (6) examined mortality and morbidity in patients <75 and 
>75 years of age with acute infarction treated with intrave- 
nous streptokinase. Their data show a 25% incidence rate of 
major hemorrhagic complications in the >75 year old age 
group compared with 11% in patients ~75 years. Mortality 
related to the hemorrhagic events was 17% versus 1% in the 
older and younger patients, respectively. There was no 
control group in that retrospective analysis, and the data do 
not permit evaluation of whether the risks of intravenous 
streptokinase in older patients outweigh the benefits. 
When consecutive patient series of coronary care unit 
admissions for acute myocardial infarction are examined for 
potential candidates for thrombolytic therapy, as many as 
30% of patients are ineligible because of age >75 years 
(7,34). The in-hospital mortality rate for these older patients 
in recent years is reported to be 21% (34). If rt-PA therapy 
can reduce this rate by 30% in patients >75 years, the 
expected in-hospital mortality rate in the treated group 
would be reduced to 14%. This reduction in in-hospital 
mortality might be offset if the risk of major bleeding events 
such as intracranial hemorrhage approaches the level of 
mortality reduction, and this issue requires additional inves- 
tigation. 
Conclusions. In a group of patients with acute myocardial 
infarction treated with rt-PA in whom a strategy of early 
catheterization is followed, in-hospital mortality significantly 
increases with age, confirming previous observations made 
before the thrombolytic era. Major hemorrhagic events are 
significantly increased in older patients. Reperfusion rates 
after rt-PA therapy in older patients are similar to those 
observed in younger patients. The incidence of hemorrhagic 
events observed in the TIM1 Phase I and open label studies 
are relatively high because 1) urgent cardiac catheterization 
was required by protocol in all patients, and 2) an rt-PA dose 
of 150 mg was used in 49.9% of the total study group. We 
expect that hemorrhagic events will be significantly less 
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frequent with an rt-PA dose of 100 mg and with early cardiac 
catheterization in older patients being reserved for the 
subgroup of patients who demonstrate hemodynamic insta- 
bility, recurrent myocardial ischemia or other well defined 
clinical indications. A randomized placebo-controlled study 
of t-t-PA in patients >76 years of age with acute myocardial 
infarction would be of definite interest. 
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